This provider's $15.9M in total Medicare payments ranks in the 94th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 7428% from 2018 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 3393% in 2019
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2018 | $410.96 | $157.91 | 2.60x | $253.05 | $16.3K | 100 | 100 |
| 2019 | $472.32 | $219.72 | 2.15x | $252.60 | $567.7K | 3.4K | 2.8K |
| 2020 | $277.47 | $96.41 | 2.88x | $181.06 | $2.8M | 38.7K | 11.3K |
| 2021 | $117.12 | $45.93 | 2.55x | $71.19 | $8.0M | 188.1K | 17.6K |
| 2022 | $153.98 | $61.99 | 2.48x | $91.99 | $3.3M | 78.1K | 10.2K |
| 2023 | $152.42 | $58.78 | 2.59x | $93.64 | $1.2M | 26.3K | 5.6K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 115.9K | $9.1M | $78.60 | 1.91x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 98.0K | $2.4M | $24.94 | 2.00x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 93.0K | $2.2M | $23.41 | 1.71x |
| 87633 | Detection test for multiple types of respiratory virus | 1.9K | $809.9K | $426.70 | 3.04x |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 12.8K | $644.5K | $50.28 | 2.00x |
| 87798 | Detection test for organism | 2.8K | $98.3K | $35.56 | 3.12x |
| 87640 | Detection test for Staphylococcus aureus (bacteria) | 2.7K | $96.0K | $35.58 | 3.52x |
| 87486 | Detection test for Chlamydia pneumoniae | 2.7K | $95.0K | $35.57 | 3.09x |
| 87651 | Detection test for Strep (Streptococcus, group A) | 2.5K | $87.4K | $35.30 | 3.13x |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | 433 | $60.6K | $139.84 | 2.16x |
| 81408 | Molecular pathology procedure level 9 | 52 | $51.5K | $989.51 | 1.02x |
| 87150 | Identification of organisms by genetic analysis, amplified probe technique | 1.2K | $40.5K | $34.41 | 2.36x |
| 81201 | Gene analysis (adenomatous polyposis coli), full gene sequence | 51 | $39.0K | $764.40 | 2.09x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [S cerevisiae]) full sequence analysis | 51 | $33.8K | $662.97 | 2.19x |
| 81298 | Gene analysis (mutS homolog 6 [E coli]) full sequence analysis | 51 | $32.1K | $629.01 | 1.51x |
| 81295 | Gene analysis (mutS homolog 2, colon cancer, nonpolyposis type 1) full sequence analysis | 51 | $19.1K | $374.07 | 2.67x |
| 81406 | Molecular pathology procedure level 7 | 51 | $14.1K | $277.22 | 1.64x |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | 123 | $12.0K | $97.85 | 1.81x |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | 161 | $9.5K | $58.73 | 4.48x |
| 81404 | Molecular pathology procedure level 5 | 28 | $7.5K | $269.33 | 1.49x |
This provider submits charges 1.99 times higher than what Medicare actually pays.
A markup ratio of 1.99x means for every $100 Medicare pays, this provider initially charges $199. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in NJ for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America Holdings | Raritan, NJ | $1.2B | ⚠️ Flagged |
| Quest Diagnostics Incorporated | Clifton, NJ | $927.2M | ⚠️ Flagged |
| Bioreference Health, Llc | Elmwood Park, NJ | $841.0M | ⚠️ Flagged |
| Accu Reference Medical Lab, Llc | Linden, NJ | $204.9M | ⚠️ Flagged |
| Aculabs Inc | East Brunswick, NJ | $91.5M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data